drugset / Trial / NCT02630875
A4250, an IBAT Inhibitor in Pediatric Cholestasis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate A4250 (IBATinhibitor) as a treatment option in pediatric patients with chronic cholestasis with main emphasis on safety evaluation and on effects on pruritus
Timeline
- Start
- 2015-08
- Primary completion
- 2017-03-17
- Completion
- 2017-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Odevixibat | Small molecule | — | Oral |